Our recent agreements


Global development and commercialization rights of elacestrant, an oral SERD currently being evaluated in the EMERALD Phase 3 study as hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer. Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.

Exclusive commercialization rights of NEXPOVIO (selinexor) in Europe, Latin America, and the CIS countries. Selinexor is a first-in-class oral Selective Inhibitor of Nuclear Export (SINE), approved in the US for multiple myeloma and under Accelerated Approval for diffuse large B-cell lymphoma and approved in the EU under a Conditional Marketing Authorization for multiple myeloma. Selinexor is being developed for the treatment of additional hematologic and solid tumor indications.

With this collaboration, we are one step closer toward fulfilling our mission to prolong patients’ lives.


NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

June 28, 2022 - Exclusive licensing deal between NewAmsterdam Pharma and the Menarini Group to commercialize obicetrapib in Europe. Obicetrapib is a next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor therapeutic candidate, currently in multiple, global phase 3 development for LDL-lowering and cardiovascular events prevention as adjunct treatment  in patients with dyslipidemia despite maximally tolerated statin therapy. The collaboration expands Menarini's existing cardiology portfolio of 18 products, which address the most widespread cardiometabolic diseases and aim to prevent and reduce risk factors associated with chronic conditions. Obicetrapib, if approved, could radically alter the treatment landscape in cardiovascular disease by providing an effective and oral option for hyperlipidemia patients in Europe.


Menarini strengthened its respiratory value proposition with various commercial deals in Asthma and COPD for GSK’s Ellipta’s Portfolio (LABA, LAMA, LAMA/LABA). In addition, Nucala® (mepolizumab) is also included for severe Asthma


Melinta and Menarini have entered into a commercial and co-development agreement for Quofenix®, Vaborem™, Orbactiv® and Minocin® in 68 countries, thus building a high value antinfectives platform.

Venatorx Pharmaceuticals and Menarini Group entered into a commercial agreement for Cefepime-Taniborbactam in 96 countries. Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic combination being developed for the treatment of complicated urinary tract infections (cUTIs), and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).